Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Cancer Res. 2016 Jan 29;76(6):1653–1663. doi: 10.1158/0008-5472.CAN-15-2510

Figure 1.

Figure 1

Brk is induced following dex treatment of primary human TNBC explants and cell lines. (A) Explant experimental model and quantification of Brk mRNA levels explants. (B) Patient tumor explants were treated for 24hrs with vehicle or 10μM dex and subjected to Western blot analysis (two representative explants) Brk, GR, and Actin (loading control) antibodies. Paired (same tumor) mRNA levels were analyzed by qRT-PCR and normalized to 18S expression. (C) MDA-MB-231, Hs578T, and BT-20 cells were treated with increasing doses or 1μM dex for 24hrs and mRNA levels were analyzed by qRT-PCR after normalization to Actin, TBP, or 18S (Asterisks (**) indicate statistical significance (p<0.01; an unpaired Student t test)).